They Call It a Lottery Ticket. The Data Says Otherwise | The Hidden Alpha of Biotech

Why It Matters

Understanding biotech’s valuation mechanics and cycle dynamics helps investors allocate capital efficiently, as specialist insight can generate outsized returns when macro conditions favor the sector.

Key Takeaways

• Biotech valuation hinges on long‑term cash‑flow discounting significantly
• Success rates drop from pre‑clinical (5‑10%) to later phases
• Specialist knowledge creates persistent alpha in public biotech markets
• Rising rates and AI hype diverted capital from biotech recently
• Post‑2025 capital influx revived biotech returns, signaling new cycle

Summary

Biotech investing is portrayed as a lottery ticket, yet specialist investors argue persistent alpha exists. The conversation with DA Wallak explores how early‑stage biotech firms are valued using a “bag of options” framework that sums the net present value of each drug program, adjusting for phase‑specific success probabilities and future cash‑flows.

Key insights include the low base‑rate of success—roughly 5‑10% from pre‑clinical to approval—and the importance of accurate reference classes for antibodies versus small molecules. Valuations are highly sensitive to discount rates because cash‑flows often lie eight to ten years ahead, making rising interest rates a major headwind.

Wallak notes that the pandemic created a temporary “sugar high” for biotech, followed by a capital exodus as investors chased AI and big‑tech narratives. The sector’s cyclical nature resurfaced in mid‑2025, with passive biotech indexes delivering 80‑100% returns as capital returned.

The implication is that disciplined, knowledge‑intensive investors can capture outsized returns by correctly estimating success probabilities and market size, especially when macro conditions—interest rates and competing narratives—shift. As biotech re‑enters a growth phase, the hidden alpha may become more accessible but remains contingent on specialist analysis.

Original Description

Biotech is one of the few areas in investing where specialized knowledge may still generate persistent alpha. In this episode of Excess Returns, D.A. Wallach, venture capitalist and co-founder of Time BioVentures, joins us to explain how biotech investing works, why development-stage drug companies behave like portfolios of options, and why specialist investors play such a large role in this market. We also explore the cycles that have driven biotech performance, the impact of interest rates and capital flows, and how AI and global competition may reshape the industry in the years ahead.

D.A. Wallach – Twitter

[https://x.com/DAWallach](https://x.com/DAWallach)

Topics covered include

• Why biotech may be one of the last areas where specialist investors can generate persistent alpha

• The “bag of options” framework for valuing development-stage biotech companies

• How probabilities of drug success and clinical base rates drive biotech valuations

• Why rising interest rates hit biotech stocks harder than many other sectors

• How capital flows and investor narratives create boom-and-bust cycles in biotech

• What happened to biotech during the pandemic surge and the post-COVID downturn

• Why AI and tech narratives compete with biotech for investor attention

• The role of specialist biotech hedge funds in the public markets

• How large pharmaceutical companies drive returns through biotech acquisitions

• Differences between biotech venture capital and traditional tech venture investing

• How venture investors evaluate drug development programs and scientific evidence

• Portfolio construction and diversification when investing in highly uncertain biotech companies

• The emerging role of China in clinical trials and global drug development

• Whether AI can improve drug discovery, clinical trials, and pharmaceutical R&D productivity

• Why investors should avoid rigid value vs growth ideologies and stay adaptable

Timestamps

00:00 Why biotech investing requires specialized knowledge

01:40 Is biotech one of the last places for persistent active alpha?

02:45 The “bag of options” model for valuing biotech companies

05:00 Drug development phases and probabilities of success

07:00 Using base rates to estimate clinical trial success

09:20 Estimating total addressable markets for new drugs

11:10 Why rising interest rates hurt biotech valuations

13:00 Capital flows and why biotech underperformed in recent years

15:30 The biotech boom and bust around the COVID pandemic

18:00 How AI and tech compete with biotech for investor capital

22:20 The role of specialist biotech hedge funds

24:00 How pharmaceutical acquisitions drive biotech returns

25:20 How biotech venture capital differs from tech VC

30:50 Why biotech investors must evaluate complex scientific data

34:20 Where AI may improve drug discovery and R&D productivity

42:00 Portfolio construction and diversification in biotech venture investing

44:30 Volatility, valuation marks, and private market pricing

48:00 Managing risk across different drug technologies and disease areas

49:30 Why China is becoming important for clinical trials

53:00 Why biotech investing must be viewed as a global industry

54:30 The importance of flexibility between value and growth investing

58:50 Will investing become more systematic and quantitative over time